Aegerion Pharmaceuticals Inc

Aegerion Pharmaceuticals — Merger or Acquisition (June 2016)

15 slides from Aegerion Pharmaceuticals's merger presentation, Jun 16, 2016

  1. Slide 1: Cautionary Note on Forward Looking Statements

    Cautionary Note on Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,

  2. Slide 2: Important Information for Investors and Shareholders

    Important Information for Investors and Shareholders Additional Information about the Proposed Transaction and Where to Find It This communication does not constitute an offer to buy or solicitation of any offer to sell securities or a solicitation of any vote or approval. It does not constitute a p

  3. Slide 3: Transaction Highlights

    Transaction Highlights QLT Inc. (“QLT”) and Aegerion Pharmaceuticals, Inc. (“Aegerion”) are a Strong Strategic Fit QLT accesses a global, rare disease company with capability to commercialize its promising asset, QLT091001 (Zuretinol acetate; “Zuretinol”), if approved Aegerion addresses capital need

  4. Slide 4: Aegerion & QLT Create a Strong, Global Rare-Disease Focused Organization

    Aegerion & QLT Create a Strong, Global Rare-Disease Focused Organization 5 Core Attributes Aegerion QLT Novelion Strong Cash Position On-Market Growth Products Late Stage Orphan Clinical Asset Global Capabilities Commercial Infrastructure Rare Disease Core Competency Leadership / Board Strong Invest

  5. Slide 5: Inherited Retinal Diseases (IRD) – A Significant Unmet Need

    Inherited Retinal Diseases (IRD) – A Significant Unmet Need Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) caused by LRAT or RPE65 mutations are forms of IRD These gene defects result in severely or completely compromised visual cycle There are currently no FDA or EMA approved pharma

  6. Slide 6: Prevalence of LCA and RP

    Prevalence of LCA and RP LCA and RP Population with RPE65/LRAT Mutations (U.S. and EU3) Key Insights The 2015 prevalent population of RP and LCA patients estimated to have RPE65 or LRAT in the U.S. and the EU3 is ~2,000 patients Prevalence estimates worldwide: 1.8 1.6 1.4 1.2 1 0.8 0.6 0.4 0.2 0 RP:

  7. Slide 7: Zuretinol – A Unique Therapeutic Opportunity

    Zuretinol – A Unique Therapeutic Opportunity Zuretinol acts as a replacement of a missing component of the visual cycle (11-cis-retinal) in LCA and RP patients with RPE65 or LRAT gene defects Oral solution for QD dosing 3-5 day course of therapy once monthly Demonstrated improvements in Goldmann Vis

  8. Slide 8: Zuretinol Clinical Summary – Single Seven-Day Dose (IRD01 Study)

    Zuretinol Clinical Summary – Single Seven-Day Dose (IRD01 Study) GVF Assessments of an LCA Patient Pre-and Post-Dosing Patients Achieving > 20% Increase in GVF Area or > 5 Letter Improvement in VA in at Least 1 Eye at 2 or More Consecutive Visits within 2 Mos. Of Treatment 80% 70% 60% 50% 40% 30% 20

  9. Slide 9: Zuretinol Clinical Summary – Repeated Seven-Day Dose (IRD02 Study)

    Zuretinol Clinical Summary – Repeated Seven-Day Dose (IRD02 Study) Retreatment trial for IRD01 patients Up to 3 additional 7-day treatment courses (with a minimum of 1 month between courses) Patients Achieving > 20% Increase in GVF Area or > 5 Letter Improvement in VA in at Least 1 Eye at 2 or More

  10. Slide 10: GVF Response to Repeated 7-Day Dosing in an LCA Patient

    GVF Response to Repeated 7-Day Dosing in an LCA Patient LCA patient* (female, 15 years old) from prior IRD01 and IRD02 studies Retreatment with Zuretinol improves GVF several-fold following each repeated 7-day dosing Improvements in GVF area were maintained for 1 – 2 months Patient also reported: Im

  11. Slide 11: Anticipated Timing for Key Potential Milestones

    Anticipated Timing for Key Potential Milestones Reimbursement 2015 2016 2017 2018 2019 2020 Phase 3 Study (QLT091001 Zuretinol) 12 Initiation of Zuretinol FDA / EMA Filing Zuretinol FDA / EMA Full Approval Zuretinol Myalept Myalept EMA GL Approval and U.S. / EMA SPL Approval EMA Filing Juxtapid Japa

  12. Slide 12: Transaction Structure and Financial Highlights

    Transaction Structure and Financial Highlights Acquisition of Aegerion via merger in 100% stock transaction; Aegerion to become wholly-owned indirect subsidiary of QLT: Exchange Ratio. The exchange ratio of 1.0256 shares of QLT common stock for each share of Aegerion common stock is subject to certa

  13. Slide 13: Novelion: A Strong, Global Rare-Disease Focused Organization

    Novelion: A Strong, Global Rare-Disease Focused Organization Transformation Late-stage, rare disease asset providing longer-term risk mitigation and significant revenue and upside potential Significant cash position Preliminary agreements in principle with SEC / DOJ Blue-chip shareholder support New

  14. Slide 14: Questions

    Aegerion· Pharmaceuticals QLT Inc. Questions 15

  15. Slide 15: Questions

    @ Aegerion QUT Ine. Pharmaceuticals Questions

Aegerion Pharmaceuticals — Merger or Acquisition (June 2016) on 6ix